Modulari-T’s MARC Platform is set to advance cell and gene therapy with a new biochemical design for CAR-T therapies, aiming to overcome current safety concerns and high costs associated with cancer treatments. Their innovative approach promises improved efficacy and safety, potentially making CAR-T therapy a primary cancer treatment and reducing the reliance on chemotherapy. The company is in the process of securing a $3 million investment and plans to spend the next five years advancing their approach through preclinical experiments and clinical trials. If successful, this could significantly impact cancer treatment practices and overall healthcare costs.

“BioTechnology is really picking up in Montreal right now, so there’s going to be a lot of demand to build a network of founders. We’re just at the beginning of a wave, and I hope it’s gonna become a tidal wave.” - David Cotnoir-White